Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tourmaline Bio, Inc. - Common Stock (NQ: TRML ) 14.21 -0.49 (-3.33%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Tourmaline Bio, Inc. - Common Stock Tourmaline Bio to Present at the Jefferies Global Healthcare Conference May 23, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial May 16, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights May 13, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Avalo Therapeutics Appoints Biotech Leaders to Board of Directors April 02, 2024 From Avalo Therapeutics Via GlobeNewswire Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights March 19, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares January 29, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Announces Pricing of Public Offering of Common Stock January 25, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Announces Proposed Public Offering of Common Stock January 24, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD) January 08, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals December 29, 2023 Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. Via MarketBeat Tourmaline Bio added to the NASDAQ Biotechnology Index December 15, 2023 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board December 14, 2023 From Tourmaline Bio, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.